Engine Biosciences: $27 Million Secured To Advance Development Of Precision Oncology Medicines
By Amit Chowdhry ● Nov 10, 2023
Engine Biosciences - a company leveraging machine learning and high-throughput biology to discover and develop precision oncology medicines - recently announced the completion of a $27 million Series A extension. The funding round was led by Polaris Partners, with participation from both new and existing investors, bringing the total funds raised since inception to $86 million. Additional participating investors include existing investors ClavystBio (a life sciences venture investor set up by Temasek), Invus, and EDBI (Singapore-based global investor), and new investors Coronet Ventures (a Singapore-based investment entity of Cedars Sinai Intellectual Property Company) and SEEDS Capital (investment arm of Enterprise Singapore). In connection with the funding, Wen Qi Ho, Ph.D., Therapeutics Lead at ClavystBio, joined Engine’s Board of Directors.